文献速递乳腺癌

高危原发性乳腺癌强化剂量密集化疗十年随访:iddEPC对比常规方案生存更优

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
PubMed 文献 · Ann Oncol · 2018-01-01

AGO III期试验纳入1284例≥4枚腋窝淋巴结阳性的高危原发性乳腺癌患者,随机接受iddEPC(表柔比星、紫杉醇、环磷酰胺序贯q2w)或EC→P(q3w)辅助化疗。中位随访122个月,iddEPC组无事件生存率和总生存率均显著优于标准组,10年绝对OS差异达10%。

要点

  • iddEPC组10年EFS为56%,标准EC→P组为47%,HR 0.74。
  • iddEPC组10年OS为69%,标准组为59%,HR 0.72,绝对差异10%。
  • iddEPC组继发性髓系白血病/骨髓增生异常综合征9例,标准组2例。

核心结论

  • 与常规剂量EC→P相比,iddEPC在高危原发性乳腺癌中此前报告的OS获益进一步增加,10年随访时达到10%的绝对差异。

研究设计与样本

  • AGO III期随机对照试验,1998年12月至2003年4月入组1284例≥4枚腋窝淋巴结阳性的原发性乳腺癌患者。
  • 患者随机接受iddEPC(表柔比星、紫杉醇、环磷酰胺各3周期序贯q2w)或标准EC→P(表柔比星/环磷酰胺序贯紫杉醇q3w);主要终点为无事件生存率(EFS)。
  • iddEPC组658例,EC→P组626例;中位随访122个月。

主要发现

  • 10年EFS:标准组47%(95%CI 43%–52%)vs iddEPC组56%(95%CI 52%–60%),HR 0.74(95%CI 0.63–0.87),log-rank P=0.00014(单侧)。
  • 10年OS:标准组59%(95%CI 55%–63%)vs iddEPC组69%(95%CI 65%–73%),HR 0.72(95%CI 0.60–0.87),log-rank P=0.0007(双侧)。
  • EFS获益独立于绝经状态、激素受体状态或HER2状态。
  • 继发性髓系白血病/骨髓增生异常综合征:iddEPC组9例 vs EC→P组2例。

临床怎么用

  • 对于≥4枚腋窝淋巴结阳性的高危原发性乳腺癌患者,iddEPC方案较常规EC→P方案在10年随访中显示更优的EFS和OS。
  • iddEPC组继发性髓系白血病/骨髓增生异常综合征发生例数高于标准组(9例 vs 2例)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary breast cancer (BC) patients with extensive axillary lymph-node involvement have a limited prognosis. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) trial compared intense dose-dense (idd) adjuvant chemotherapy with conventionally scheduled chemotherapy in high-risk BC patients. Here we report the final, 10-year follow-up analysis. PATIENTS AND METHODS: Enrolment took place between December 1998 and April 2003. A total of 1284 patients with 4 or more involved axillary lymph nodes were randomly assigned to receive 3 courses each of idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w or standard epirubicin/cyclophosphamide followed by paclitaxel (EC → P) q3w. Event-free survival (EFS) was the primary end point. RESULTS: A total of 658 patients were assigned to receive iddEPC and 626 patients were assigned to receive EC → P. The median duration of follow-up was 122 months. EFS was 47% (95% CI 43% to 52%) in the standard group and 56% (95% CI 52% to 60%) in the iddEPC group [hazard ratio (HR) 0.74, 95% CI 0.63-0.87; log-rank P = 0.00014, one-sided]. This benefit was independent of menopausal, hormone receptor or HER2 status. Ten-year overall survival (OS) was 59% (95% CI 55% to 63%) for patients in the standard group and 69% (95% CI 65% to 73%) for patients in the iddEPC group (HR = 0.72, 95% CI 0.60-0.87; log-rank P = 0.0007, two-sided). Nine versus two cases of secondary myeloid leukemia/myelodysplastic syndrome were observed in the iddEPC and the EC → P arm, respectively. CONCLUSION: The previously reported OS benefit of iddEPC in comparison to conventionally dosed EC → P has been further increased and achieved an absolute difference of 10% after 10 years of follow-up.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Möbus V, Jackisch C, Lück HJ, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018. PMID: 29069370. doi:10.1093/annonc/mdx690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。